The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA

By Josiane E. Garneau, M. Dupuis, M. Villion, D. Romero, Rodolphe Barrangou, Patrick Boyaval, C. Fremaux, Philippe Horvath, A. H. Magadán, Sylvain Moineau. Nature, 2010

2,207 citations recorded by the source corpus.

Subfields: Ecology, Endocrinology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a5ef85afc7ace2d97507b1153074e628aa8632b9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ecology

1. Jennifer A. Doudna
2. Eugene V. Koonin
3. Feng Zhang
4. Rodolphe Barrangou
5. L. Marraffini
6. Kira S. Makarova
7. J. van der Oost
8. E. Charpentier

In Endocrinology

1. Feng Zhang
2. Bernd H. A. Rehm
3. Phillip A. Sharp
4. Rodolphe Barrangou
5. Eugene V. Koonin
6. L. Marraffini

In Molecular Biology

1. Jennifer A. Doudna
2. Feng Zhang
3. Rodolphe Barrangou
4. Lei S. Qi
5. Eugene V. Koonin
6. P. Hsu
7. E. Charpentier
8. Kira S. Makarova

Citations in the corpus

• The Biology of CRISPR-Cas: Backward and Forward. (2018, positive): “If the target displays sufficient complementarity to the RNA guide, Cas9 generates a blunt, double-strand break 3 bp upstream of the PAM (Garneau et al., 2010; Jinek et al., 2012).”
• CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity (2014, background): “A study in 2010 showed this CRISPR-Cas system can also vaccinate cells against plasmid uptake by adaptive spacer acquisition (Garneau et al., 2010).”
• CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. (2011, background): “This initiates cleavage of the crRNA–foreign nucleic acid complex (30).”
• Crystal structure of Cpf1 in complex with guide RNA and target DNA (2016, background): “, 2015), whereas Cas9 creates blunt ends within the PAM-proximal target site (Garneau et al., 2010).”
• RNA-Guided Human Genome Engineering via Cas9 (2013, neutral): “thermophilus (35); however, similar degeneracy was not sufficient to block phage infection (31), emphasizing the importance of the assay utilized.”
• Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis (2013, background): “Importantly,mostCRISPR-Cas subtypes targetDNA directly (13, 19, 20), suggesting the possibility of engineered, RNAdirected gene-targeting/editing systems.”
• Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis (2015, background): “Recently, the Cas9 nuclease (Barrangou et al., 2007; Bolotin et al., 2005; Chylinski et al., 2013, 2014; Deltcheva et al., 2011; Garneau et al., 2010; Gasiunas et al., 2012; Jinek et al., 2012; Sapranauskas et al., 2011) from the microbial type II CRISPR (clustered regularly interspaced short palind”
• The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli (2011, background): “Direct spacer acquisition activity has been demonstrated for the CRISPR1 and CRISPR3 systems, with the former being more active in this strain (3,12,13).”
• Target specificity of the CRISPR-Cas9 system (2014, neutral): “The PAM is recognized by an individual domain in the Cas9 protein [56], and the PAM sequence varies across bacteria species [57,58].”